United Therapeutics (UTHR) Tops Q1 EPS by 19c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
JMP Securities Downgrades SteadyMed (STDY) to Market Perform Following Acquisition
May 1, 2018 3:25 AM EDTJMP Securities downgraded SteadyMed (NASDAQ: STDY) from Market Outperform to Market Perform.
Analyst Donald Ellis steps to the sideline following the recent acquisition by United Therapeutics (NASDAQ: UTHR). The analyst is not expecting a competing offer to... More
Pre-Open Movers 04/30: (STDY) (ANDV) (FDC) Higher; (CTB) (S) (ARNC) Lower (more...)
April 30, 2018 9:27 AM EDTToday's Pre-Open Movers
SteadyMed Ltd. (NASDAQ: STDY) 81.1% HIGHER; United Therapeutics Corporation (NASDAQ: UTHR) and SteadyMed Ltd. (NASDAQ: STDY) announced today the signing of a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $4.46 per share in cash at closing and an additional $2.63 per share in cash upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
Pluristem Therapeutics Inc. (Nasdaq:... More
